Podrobno

Defining bath ankylosing spondylitis disease activity index cut-off values for disease activity states in a multinational european cohort of patients with axial spondyloarthritis
ID Georgiadis, Stylianos (Avtor), ID Rotar, Žiga (Avtor), ID Perdan-Pirkmajer, Katja (Avtor), ID Midtbøll Ørnbjerg, Lykke (Avtor), ID Michelsen, Brigitte (Avtor), ID Perdan-Pirkmajer, Katja (Avtor)

.pdfPDF - Predstavitvena datoteka, prenos (1,21 MB)
MD5: D03FB1BFBFBE0FDADCF305C6F07498B0
URLURL - Izvorni URL, za dostop obiščite https://pmc.ncbi.nlm.nih.gov/articles/PMC12670041/pdf/ACR2-7-e70125.pdf Povezava se odpre v novem oknu

Izvleček
Objective: The Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) is widely used for assessing disease activity in patients with axial spondyloarthritis (axSpA), particularly in settings where markers of inflammation are unavailable. As no consensus on BASDAI cut-off values exists for disease activity states in axSpA, we aimed to develop and validate such cut-offs against external criteria. Methods: Routine care patients with axSpA initiating a biologic disease-modifying antirheumatic drug in eight European registries were included. Receiver operating characteristic analyses against external criteria were performed to determine optimal BASDAI values for separating remission, low disease activity (LDA), high disease activity (HDA), and very high disease activity (VHDA). Follow-up data at 6 months were used to select BASDAI cut-off values between remission and LDA and between LDA and HDA, whereas baseline data were used to select the cut-off for VHDA. The level of agreement between disease activity states based on BASDAI and Axial Spondyloarthritis Disease Activity Score (ASDAS) cut-off values was assessed using the proportion of discordance and weighted kappa. Results: In this cohort of 4,633 patients, the optimal BASDAI cut-off values between remission, LDA, HDA and VHDA were estimated to be <1.3, <2.5, and >5.3. The proportions of discordance between BASDAI and ASDAS disease activity states were 27.6% (weighted κ = 0.48) in baseline data and 37.6% (weighted κ = 0.28) in 6-month data. Conclusion: BASDAI cut-off values for separating remission, LDA, HDA and VHDA were estimated in >4,600 patients. These cut-off values can be used for assessing disease activity and monitoring patients with axSpA, particularly when laboratory markers are unavailable.

Jezik:Angleški jezik
Ključne besede:disease activity states, ankylosing spondylitis, axial spondyloarthritis, multinational European cohort
Vrsta gradiva:Članek v reviji
Tipologija:1.01 - Izvirni znanstveni članek
Organizacija:MF - Medicinska fakulteta
Status publikacije:Objavljeno
Različica publikacije:Objavljena publikacija
Leto izida:2025
Št. strani:11 str.
Številčenje:Vol. 7, iss. 12, art. e70125
PID:20.500.12556/RUL-177935 Povezava se odpre v novem oknu
UDK:616-002
ISSN pri članku:2578-5745
DOI:10.1002/acr2.70125 Povezava se odpre v novem oknu
COBISS.SI-ID:261989635 Povezava se odpre v novem oknu
Datum objave v RUL:15.01.2026
Število ogledov:532
Število prenosov:150
Metapodatki:XML DC-XML DC-RDF
:
Kopiraj citat
Objavi na:Bookmark and Share

Gradivo je del revije

Naslov:ACR open rheumatology
Skrajšan naslov:ACR open rheumatol.
Založnik:Wiley & Sons
ISSN:2578-5745
COBISS.SI-ID:529833497 Povezava se odpre v novem oknu

Licence

Licenca:CC BY-NC 4.0, Creative Commons Priznanje avtorstva-Nekomercialno 4.0 Mednarodna
Povezava:http://creativecommons.org/licenses/by-nc/4.0/deed.sl
Opis:Licenca Creative Commons, ki prepoveduje komercialno uporabo, vendar uporabniki ne rabijo upravljati materialnih avtorskih pravic na izpeljanih delih z enako licenco.

Sekundarni jezik

Jezik:Slovenski jezik
Ključne besede:stanja aktivnosti bolezni, a nkilozirajoči spondilitis, aksialni spondiloartritis, multinacionalna evropska kohorta

Projekti

Financer:Novartis Pharma AG

Financer:UCB Biopharma SRL

Podobna dela

Podobna dela v RUL:
Podobna dela v drugih slovenskih zbirkah:

Nazaj